NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-disclosure, pharmaceuticals
TL;DR
NRX Pharma filed an 8-K on Oct 17, 2025, covering Reg FD, other events, and financials.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting events as of October 17, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing provides an update on NRX Pharmaceuticals' corporate activities and disclosures, which is important for investors to stay informed about the company's regulatory compliance and business events.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Numbers
- 001-38302 — SEC File Number (Identifies the company's filing with the SEC)
- 82-2844431 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- October 17, 2025 (date) — Earliest event reported date
- October 23, 2025 (date) — Filing date
- Delaware (location) — State of incorporation
FAQ
What specific events are disclosed under 'Other Events' in this 8-K filing?
The provided text does not detail the specific 'Other Events', only that it is an item reported in the 8-K.
What is the significance of the 'Regulation FD Disclosure' item?
Regulation FD (Fair Disclosure) ensures that material information is disclosed to all investors simultaneously, preventing selective disclosure.
When did NRX Pharmaceuticals change its name from Big Rock Partners Acquisition Corp.?
The date of the name change was October 12, 2017.
What is the principal executive office address for NRX Pharmaceuticals?
The principal executive offices are located at 1201 Orange Street, Suite 600, Wilmington, Delaware 19801.
What is the SIC code for NRX Pharmaceuticals?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-23 16:31:30
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
Filing Documents
- nrxp20251023_8k.htm (8-K) — 35KB
- ex_875021.htm (EX-99.1) — 16KB
- nrxlogo.jpg (GRAPHIC) — 2KB
- 0001437749-25-031637.txt ( ) — 206KB
- nrxp-20251017.xsd (EX-101.SCH) — 4KB
- nrxp-20251017_def.xml (EX-101.DEF) — 14KB
- nrxp-20251017_lab.xml (EX-101.LAB) — 18KB
- nrxp-20251017_pre.xml (EX-101.PRE) — 14KB
- nrxp20251023_8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 20, 2025, the Company issued a press release announcing HOPE Therapeutics' completion of the strategic interest in Cohen, LLC, as further described under Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Other Events
Item 8.01 Other Events On October 17, 2025, NRX Pharmaceuticals, Inc. (the "Company"), through its subsidiary HOPE Therapeutics, Inc., a Delaware corporation ("HOPE Therapeutics"), completed its acquisition of a strategic and minority interest in Rebecca S. Cohen, MD, LLC d/b/a Cohen & Associates, a Florida limited liability company ("Cohen, LLC"). The acquisition of the interest in Cohen, LLC was effectuated pursuant to the terms and conditions of the Membership Interest Purchase Agreement (the "Cohen Purchase Agreement"), dated October 17, 2025, by and among HOPE Therapeutics, Cohen, LLC and Rebecca S. Cohen, MD. The Cohen Purchase Agreement included customary representations and warranties and indemnification provisions and certain post-closing adjustments. In connection with the transaction, Dr. Rebecca Cohen was appointed Medical Director of HOPE Therapeutics, and the terms of employment include certain financial incentives to establish and grow new sites of care owned or operated by HOPE Therapeutics.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 20, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: October 23, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer